Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
- Casanova, M J
- Chaparro, M
- García-Sánchez, V
- Nantes, O
- Leo, E
- Rojas-Feria, M
- Jauregui-Amezaga, A
- García-López, S
- Huguet, J M
- Arguelles-Arias, F
- Aicart, M
- Marín-Jiménez, I
- Gómez-García, M
- Muñoz, F
- Esteve, M
- Bujanda, L
- Cortés, X
- Tosca, J
- Pineda, J R
- Mañosa, M
- Llaó, J
- Guardiola, J
- Pérez-Martínez, I
- Muñoz, C
- González-Lama, Y
- Hinojosa, J
- Vázquez, J M
- Martinez-Montiel, M P
- Rodríguez, G E
- Pajares, R
- García-Sepulcre, M F
- Hernández-Martínez, A
- Pérez-Calle, J L
- Beltrán, B
- Busquets, D
- Ramos, L
- Bermejo, F
- Barrio, J
- Barreiro-de Acosta, M
- Roncedo, O
- Calvet, X
- Hervías, D
- Gomollón, F
- Domínguez-Antonaya, M
- Alcaín, G
- Sicilia, B
- Dueñas, C
- Gutiérrez, A
- Lorente-Poyatos, R
- Domínguez, M
- Khorrami, S
- Muñoz, C
- Taxonera, C
- Rodríguez-Pérez, A
- Ponferrada, A
- Van Domselaar, M
- Arias-Rivera, M L
- Merino, O
- Castro, E
- Marrero, J M
- Martín-Arranz, M
- Botella, B
- Fernández-Salazar, L
- Monfort, D
- Opio, V
- García-Herola, A
- Menacho, M
- Ramírez-de la Piscina, P
- Ceballos, D
- Almela, P
- Navarro-Llavat, M
- Robles-Alonso, V
- Vega-López, A B
- Moraleja, I
- Novella, M T
- Castaño-Milla, C
- Sánchez-Torres, A
- Benítez, J M
- Rodríguez, C
- Castro, L
- Garrido, E
- Domènech, E
- García-Planella, E
- Gisbert, J P
DOIAbstract
The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included. A total of 1,055 patients were included. The incidence rate of relapse was 19% and 17% per patient-year in Crohn's disease and ulcerative colitis patients, respectively. In both Crohn's disease and ulcerative colitis patients ...
Add to ORKG